NCT00519831View on ClinicalTrials.gov

Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

PHASE2TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

November 30, 2009

Conditions
Lung Cancer
Interventions
BIOLOGICAL

cetuximab

400 mg/m² week 1,then 250 mg/m² weekly

DRUG

vinflunine

Vinflunine 320 mg/m² every 21 days

Trial Locations (2)

27216

Alamance Oncology/Hematology Associates, LLP, Burlington

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER